FR3048698B1 - Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 - Google Patents

Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 Download PDF

Info

Publication number
FR3048698B1
FR3048698B1 FR1652040A FR1652040A FR3048698B1 FR 3048698 B1 FR3048698 B1 FR 3048698B1 FR 1652040 A FR1652040 A FR 1652040A FR 1652040 A FR1652040 A FR 1652040A FR 3048698 B1 FR3048698 B1 FR 3048698B1
Authority
FR
France
Prior art keywords
bcl2
receiver
interaction inhibitors
inhibitors
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1652040A
Other languages
English (en)
Other versions
FR3048698A1 (fr
Inventor
Adrien Nougarede
Ruth Rimokh
Germain Gillet
Nikolay Popgeorgiev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Leon Berard
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Leon Berard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 UCBL, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Leon Berard filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1652040A priority Critical patent/FR3048698B1/fr
Priority to PCT/EP2017/055469 priority patent/WO2017153484A1/fr
Priority to JP2018547325A priority patent/JP2019510015A/ja
Priority to US16/081,258 priority patent/US20190030126A1/en
Priority to EP17709441.4A priority patent/EP3426679A1/fr
Priority to CN201780025917.9A priority patent/CN109311962A/zh
Publication of FR3048698A1 publication Critical patent/FR3048698A1/fr
Application granted granted Critical
Publication of FR3048698B1 publication Critical patent/FR3048698B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

La présente invention concerne un inhibiteur compétitif de la liaison de la protéine Bcl-2 L10 sur le domaine de liaison au ligand d'au moins l'un des récepteurs IP3R.
FR1652040A 2016-03-11 2016-03-11 Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 Active FR3048698B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1652040A FR3048698B1 (fr) 2016-03-11 2016-03-11 Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
PCT/EP2017/055469 WO2017153484A1 (fr) 2016-03-11 2017-03-08 Inhibiteurs de l'interaction protéine bcl-2 l10/récepteurs ip3
JP2018547325A JP2019510015A (ja) 2016-03-11 2017-03-08 Ｂｃｌ−２ ｌ１０／ｉｐ３受容体の相互作用の阻害剤
US16/081,258 US20190030126A1 (en) 2016-03-11 2017-03-08 Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors
EP17709441.4A EP3426679A1 (fr) 2016-03-11 2017-03-08 Inhibiteurs de l'interaction protéine bcl-2 l10/récepteurs ip3
CN201780025917.9A CN109311962A (zh) 2016-03-11 2017-03-08 Bcl-2 l10/ip3受体相互作用的抑制剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1652040A FR3048698B1 (fr) 2016-03-11 2016-03-11 Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3

Publications (2)

Publication Number Publication Date
FR3048698A1 FR3048698A1 (fr) 2017-09-15
FR3048698B1 true FR3048698B1 (fr) 2021-03-05

Family

ID=56372968

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1652040A Active FR3048698B1 (fr) 2016-03-11 2016-03-11 Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3

Country Status (6)

Country Link
US (1) US20190030126A1 (fr)
EP (1) EP3426679A1 (fr)
JP (1) JP2019510015A (fr)
CN (1) CN109311962A (fr)
FR (1) FR3048698B1 (fr)
WO (1) WO2017153484A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077080A1 (fr) 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 Évaluation du risque de rechute métastatique chez des patients atteints d'un cancer du sein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521548B2 (en) * 2001-02-07 2009-04-21 Burnham Institute For Medical Research Apoptosis modulator Bcl-B and methods for making and using same
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
US9657073B2 (en) 2010-09-01 2017-05-23 Case Western Reserve University Inhibitors of Bcl-2
FR2987446B1 (fr) * 2012-02-28 2016-01-01 Univ Nice Sophia Antipolis Test diagnostic de la resistance a l'azacitidine
EP2970417B1 (fr) * 2013-03-15 2019-06-19 Dana-Farber Cancer Institute, Inc. Peptides bh4 stabilisés et leurs utilisations
CA2923664C (fr) 2013-09-10 2023-05-02 Jean-Philippe PELLOIS Compositions et procedes pour l'introduction de molecules dans des cellules vivantes

Also Published As

Publication number Publication date
US20190030126A1 (en) 2019-01-31
JP2019510015A (ja) 2019-04-11
CN109311962A (zh) 2019-02-05
FR3048698A1 (fr) 2017-09-15
EP3426679A1 (fr) 2019-01-16
WO2017153484A1 (fr) 2017-09-14

Similar Documents

Publication Publication Date Title
MD3710446T2 (ro) Compuși utili pentru inhibarea CDK7
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
EA201990997A1 (ru) Двойные ингибиторы vista и путей pd-1
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MD3443009T2 (ro) Anticorpi anti-TIM-3 și compoziții
MA55511A (fr) Inhibiteurs de protéine tyrosine phosphatase
MD3369425T2 (ro) Compoziții care cuprind tulpini bacteriene
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA202091484A1 (ru) 4-азаиндольные соединения
MA41463A (fr) Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MA41669A1 (fr) Anticorps se liant a tau
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201790380A1 (ru) Ингибиторы mk2 и их применения
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EA202091665A1 (ru) Биоразлагаемый фильтр с улучшенным вкусом
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
EA201891299A1 (ru) Терапевтические антитела к cd9
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170915

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8